{
    "2019-02-20": [
        [
            {
                "time": "2018-01-02",
                "original_text": "AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "RA",
                        "Upadacitinib",
                        "FDA",
                        "Priority Review"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Notable ETF Outflow Detected - IYH, ABT, MDT, ABBV",
                "features": {
                    "keywords": [
                        "ETF",
                        "Outflow",
                        "IYH",
                        "ABT",
                        "MDT",
                        "ABBV"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "ETFs"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "U.S. settles with Teva over keeping generic drugs off market",
                "features": {
                    "keywords": [
                        "U.S.",
                        "Teva",
                        "generic drugs",
                        "market settlement"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review",
                "features": {
                    "keywords": [
                        "Roche",
                        "BLA",
                        "Lymphoma",
                        "Drug",
                        "Priority Review"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}